{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:52:16Z","timestamp":1792821136314,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41584-022-00804-5","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T07:04:25Z","timestamp":1658732665000},"page":"543-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["When underlying biology threatens the randomization principle \u2014 initial gout flares of urate-lowering therapy"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-0442","authenticated-orcid":false,"given":"Hyon K.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(62)90501-9","volume":"280","author":"JS Faires","year":"1962","unstructured":"Faires, J. S. & McCarty, D. J. Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet 280, 682\u2013685 (1962).","journal-title":"Lancet"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.semarthrit.2020.06.001","volume":"50","author":"S Stewart","year":"2020","unstructured":"Stewart, S. et al. The experience of a gout flare: a meta-synthesis of qualitative studies. Semin. Arthritis Rheum. 50, 805\u2013811 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem, A., Harris, R. P. & Forciea, M. A. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 166, 58\u201368 (2017).","journal-title":"Ann. Intern. Med."},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","volume":"13","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth, N. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat. Rev. Rheumatol. 13, 561\u2013568 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/M16-2426","volume":"166","author":"RM McLean","year":"2017","unstructured":"McLean, R. M. The long and winding road to clinical guidelines on the diagnosis and management of gout. Ann. Intern. Med. 166, 73\u201374 (2017).","journal-title":"Ann. Intern. Med."},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/M16-2401","volume":"166","author":"T Neogi","year":"2017","unstructured":"Neogi, T. & Mikuls, T. R. To treat or not to treat (to target) in gout. Ann. Intern. Med. 166, 71\u201372 (2017).","journal-title":"Ann. Intern. Med."},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/art.40031","volume":"69","author":"JD FitzGerald","year":"2017","unstructured":"FitzGerald, J. D., Neogi, T. & Choi, H. K. Editorial: do not let gout apathy lead to gouty arthropathy. Arthritis Rheumatol. 69, 479\u2013482 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"804_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64, 1431\u20131446 (2012).","journal-title":"Arthritis Care Res."},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"804_CR11","first-page":"498","volume":"35","author":"E Krishnan","year":"2008","unstructured":"Krishnan, E., Lienesch, D. & Kwoh, C. K. Gout in ambulatory care settings in the United States. J. Rheumatol. 35, 498\u2013501 (2008).","journal-title":"J. Rheumatol."},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jbspin.2018.10.008","volume":"86","author":"ZP Latif","year":"2019","unstructured":"Latif, Z. P., Nakafero, G., Jenkins, W., Doherty, M. & Abhishek, A. Implication of nurse intervention on engagement with urate-lowering drugs: a qualitative study of participants in a RCT of nurse led care. Joint Bone Spine 86, 357\u2013362 (2019).","journal-title":"Joint Bone Spine"},{"key":"804_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","volume":"37","author":"TF Yue","year":"1964","unstructured":"Yue, T. F. & Gutman, A. B. Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am. J. Med. 37, 885\u2013898 (1964).","journal-title":"Am. J. Med."},{"key":"804_CR14","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad, G. C. et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31, 2429\u20132432 (2004).","journal-title":"J. Rheumatol."},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.3949\/ccjm.75.Suppl_5.S22","volume":"75","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher, H. R. Jr & Chen, L. X. The practical management of gout. Clevel. Clin. J. Med. 75, S22\u2013S25 (2008).","journal-title":"Clevel. Clin. J. Med."},{"key":"804_CR16","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz, F. Treating to target: a strategy to cure gout. Rheumatology 48, ii9\u2013ii14 (2009).","journal-title":"Rheumatology"},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka, H. et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann. Rheum. Dis. 77, 270\u2013276 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"804_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker, M. A., MacDonald, P. A., Hunt, B. J., Lademacher, C. & Joseph-Ridge, N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27, 585\u2013591 (2008).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald, J. D. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 72, 879\u2013895 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann, R. L., Macdonald, P. A., Hunt, B. & Jackson, R. L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin. Ther. 32, 2386\u20132397 (2010).","journal-title":"Clin. Ther."},{"key":"804_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger, N. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70, 1264\u20131271 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","volume":"52","author":"E Mitha","year":"2013","unstructured":"Mitha, E. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 52, 1285\u20131292 (2013).","journal-title":"Rheumatology"},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3899\/jrheum.090370","volume":"36","author":"HR Schumacher","year":"2009","unstructured":"Schumacher, H. R. et al. Outcome domains for studies of acute and chronic gout. J. Rheumatol. 36, 2342\u20132345 (2009).","journal-title":"J. Rheumatol."},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450\u20132461 (2005).","journal-title":"N. Engl. J. Med."},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty, M. et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403\u20131412 (2018).","journal-title":"Lancet"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306, 711\u2013720 (2011).","journal-title":"JAMA"},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2100028","DOI":"10.1056\/EVIDoa2100028","volume":"1","author":"JR O\u2019Dell","year":"2022","unstructured":"O\u2019Dell, J. R. et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 1, EVIDoa2100028 (2022).","journal-title":"NEJM Evid."},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490\u20132498 (2014).","journal-title":"JAMA"},{"key":"804_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe Scleroderma. N. Engl. J. Med. 378, 35\u201347 (2018).","journal-title":"N. Engl. J. Med."},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1505467","volume":"373","author":"ST Skou","year":"2015","unstructured":"Skou, S. T. et al. A randomized, controlled trial of total knee replacement. N. Engl. J. Med. 373, 1597\u20131606 (2015).","journal-title":"N. Engl. J. Med."},{"key":"804_CR31","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"804_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"804_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 69, 203\u2013212 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"804_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni, U. Landmark analysis at the 25-year landmark point. Circ. Cardiovasc. Qual. Outcomes 4, 363\u2013371 (2011).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"804_CR35","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/ijc.29278","volume":"136","author":"X Garcia-Albeniz","year":"2015","unstructured":"Garcia-Albeniz, X., Maurel, J. & Hernan, M. A. Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials. Int. J. Cancer 136, 2444\u20132447 (2015).","journal-title":"Int. J. Cancer"},{"key":"804_CR36","first-page":"560","volume":"159","author":"MA Hernan","year":"2013","unstructured":"Hernan, M. A., Hernandez-Diaz, S. & Robins, J. M. Randomized trials analyzed as observational studies. Ann. Intern. Med. 159, 560\u2013562 (2013).","journal-title":"Ann. Intern. Med."},{"key":"804_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.2021.2825","volume":"326","author":"VA Smith","year":"2021","unstructured":"Smith, V. A., Coffman, C. J. & Hudgens, M. G. Interpreting the results of intention-to-treat, per-protocol, and as-treated analyses of clinical trials. JAMA 326, 433\u2013434 (2021).","journal-title":"JAMA"},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","volume":"377","author":"MA Hernan","year":"2017","unstructured":"Hernan, M. A. & Robins, J. M. Per-protocol analyses of pragmatic trials. N. Engl. J. Med. 377, 1391\u20131398 (2017).","journal-title":"N. Engl. J. Med."},{"key":"804_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","volume":"48","author":"L Stamp","year":"2018","unstructured":"Stamp, L. et al. Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis. Semin. Arthritis Rheum. 48, 293\u2013301 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"804_CR40","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.semarthrit.2021.11.004","volume":"51","author":"MB Morillon","year":"2021","unstructured":"Morillon, M. B. et al. Serum urate as a proposed surrogate outcome measure in gout trials: from the OMERACT working group. Semin. Arthritis Rheum. 51, 1378\u20131385 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"804_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin, T. et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis. 76, 811\u2013820 (2017).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00804-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:46:46Z","timestamp":1733939206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00804-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"14 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K.C. declares research support from Horizon and consulting fees from Allena, Horizon, LG and Protalix. N.D. declares research support from Amgen and AstraZeneca, payment\/honoraria from AbbVie and consulting fees from Arthrosi, AstraZeneca, Cello Health, Dyve Biosciences, Horizon, JW Pharmaceuticals, PK Med and Selecta. Y.Z. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}